Anti-CEACAM6 / Nonspecific cross-reacting antigen 90, clone CEACAM6/10079R

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. Nonspecific Cross-Reacting Antigen 90 antibody recognizes Carcinoembryonic antigen-related cell adhesion molecule 6, encoded by the CEACAM6 gene and also widely known as CD66c. This recombinant monoclonal antibody (clone CEACAM6/10079R) targets a heavily glycosylated, glycosylphosphatidylinositol-anchored cell surface protein belonging to the CEA family within the immunoglobulin superfamily. CEACAM6 is primarily localized to the plasma membrane of epithelial cells, where it participates in cell-cell adhesion, immune modulation, and regulation of differentiation and survival signaling pathways.Historically, CEACAM6 was described in the literature as Nonspecific cross-reacting antigen 90, often abbreviated as NCA-90, reflecting its approximate 90 kDa apparent molecular weight on SDS-PAGE due to extensive glycosylation. The term NCA distinguished it from classical CEA, yet acknowledged antigenic cross-reactivity within the carcinoembryonic antigen family. Over time, molecular cloning and gene characterization unified these names under CEACAM6, while CD66c became the standardized cluster of differentiation designation. Because older pathology and tumor marker studies frequently use NCA-90 terminology, incorporating Nonspecific Cross-Reacting Antigen 90 antibody as a primary keyword supports strong legacy SEO capture alongside modern CEACAM6 antibody searches.CEACAM6 is highly expressed in normal epithelial tissues including colon, stomach, pancreas, and lung, with membranous localization along apical surfaces. Functionally, it contributes to intercellular adhesion and interacts with other CEACAM family members to influence tissue architecture. Beyond structural roles, CEACAM6 participates in signaling pathways that regulate apoptosis resistance, cellular proliferation, and invasion. Its overexpression has been documented in colorectal carcinoma, pancreatic ductal adenocarcinoma, gastric carcinoma, breast cancer, and lung adenocarcinoma, where it is associated with tumor progression, metastatic potential, and altered immune interactions.As a GPI-anchored protein lacking a transmembrane cytoplasmic tail, CEACAM6 signals through lateral membrane interactions and co-clustering with other adhesion molecules. It has been implicated in modulation of integrin signaling, anoikis resistance, and inflammatory responses within the tumor microenvironment. Elevated CEACAM6 expression may correlate with chemoresistance and poor clinical prognosis in several epithelial malignancies, making CEACAM6 antibody reagents valuable tools for both translational research and biomarker investigations.This recombinant monoclonal clone CEACAM6/10079R provides consistent, defined specificity for detecting CEACAM6 expression in research applications. A Nonspecific Cross-Reacting Antigen 90 antibody is suitable for evaluating membranous CEACAM6 expression patterns in epithelial tissues and carcinomas, supporting studies of tumor biology, adhesion signaling, and immune regulation. The recombinant format ensures batch-to-batch consistency and defined sequence identity, supporting reproducible experimental performance.Strong alternative terminology for CEACAM6 antibody includes CD66c antibody, NCA-90 antibody, and carcinoembryonic antigen-related cell adhesion molecule 6 antibody, all of which appear in peer-reviewed literature and pathology references. Incorporating these synonyms ensures comprehensive discoverability while maintaining scientific clarity around CEACAM6 gene identity and protein function.